Established in 2023 and headquartered in California, A venture capital firm invests in Seed-Series B companies in pre-clinical and clinical stages. The firm’s current portfolio contains USA based companies, and they are looking to expand their investments into European companies. The firm is investing from its first fund valued at $100M. Depending on investment stage, the firm will invest between $1M-$10M. The firm is open to global investments.
The firm is focused on investing in neuroscience-based technology companies and will invest in medical devices and diagnostics. The firm does not invest in therapeutic (drug) companies. Indications of interest are focused on brain disorders, with a particular interest in neurodegenerative, neurodevelopmental, and neuropsychiatric conditions including Parkinson’s disease, autism spectrum disorder, and bipolar disorder. The firm applies a broad definition to the technology solution space for these clinical conditions to include therapeutic medical devices (non-invasive and invasive), data platforms, imaging platforms, drug-device combinations, therapy enabling tools, and research tools.
The firm is open to leading or co-investing. The firm prefers, however, to lead and will generally prefer a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment